Albireo Provides First Quarter 2018 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
May 17, 2018 7:31 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($0.15), versus $1.77 reported last year. Revenue for the quarter came in at $11.2 million versus the consensus estimate of $31.32 million.
The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and Chief Executive... More
